Julia Balaguer
Overview
Explore the profile of Julia Balaguer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
199
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanchez-Vano R, Balaguer J, Borrego-Dorado I, Esteban-Figueruelo A, Gamez C, Hladun R, et al.
Clin Transl Oncol
. 2024 Nov;
PMID: 39508974
Neuroblastoma (NB) is the most common extracranial solid cancer in children. Despite intensive multimodality treatment, long-term survival of patients with high-risk NB, which comprises more than half of all cases,...
2.
de Beijer I, van den Oever S, Charalambous E, Cangioli G, Balaguer J, Bardi E, et al.
J Med Internet Res
. 2024 May;
26:e49910.
PMID: 38696248
Background: To overcome knowledge gaps and optimize long-term follow-up (LTFU) care for childhood cancer survivors, the concept of the Survivorship Passport (SurPass) has been invented. Within the European PanCareSurPass project,...
3.
de Beijer I, Hardijzer E, Haupt R, Grabow D, Balaguer J, Bardi E, et al.
J Cancer Surviv
. 2024 Mar;
PMID: 38466480
No abstract available.
4.
de Beijer I, Hardijzer E, Haupt R, Grabow D, Balaguer J, Bardi E, et al.
J Cancer Surviv
. 2023 Nov;
PMID: 38015382
Purpose: To identify barriers and facilitators for implementing the Survivorship Passport (SurPass) v2.0 in six long-term follow-up (LTFU) care centres in Europe. Methods: Stakeholders including childhood cancer survivors (CCSs), healthcare...
5.
Reinal I, Ontoria-Oviedo I, Selva M, Casini M, Peiro-Molina E, Fambuena-Santos C, et al.
Antioxidants (Basel)
. 2023 Jul;
12(7).
PMID: 37507917
Anthracyclines are widely used in the treatment of many solid cancers, but their efficacy is limited by cardiotoxicity. As the number of pediatric cancer survivors continues to rise, there has...
6.
Urtasun A, Olivera G, Sendra L, Alino S, Berlanga P, Gargallo P, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900216
Background: Pharmacogenetics is a personalized medicine tool that aims to optimize treatments by adapting them to each individual's genetics, maximizing their efficacy while minimizing their toxicity. Infants with cancer are...
7.
van den Oever S, de Beijer I, Kremer L, Alfes M, Balaguer J, Bardi E, et al.
J Cancer Surviv
. 2023 Feb;
18(3):928-940.
PMID: 36808389
Purpose: Long-term follow-up (LTFU) care for childhood cancer survivors (CCSs) is essential to improve and maintain their quality of life. The Survivorship Passport (SurPass) is a digital tool which can...
8.
Balaguer J, Garcia Hidalgo L, Hladun R, Marquez Vega C, Perez Alonso V
Target Oncol
. 2022 Dec;
18(1):77-93.
PMID: 36504394
The anti-GD2 antibody dinutuximab beta (Qarziba) has been added to the present standard of care for patients with high-risk neuroblastoma in Europe based on the positive results obtained in different...
9.
Gargallo P, Oltra S, Tasso M, Balaguer J, Yanez Y, Dolz S, et al.
Eur J Hum Genet
. 2022 Apr;
30(11):1288-1291.
PMID: 35459888
CTCF germline mutations have been related to MRD21. We report the first bilateral Wilms tumor suffered by a MRD21 patient carrying an unreported CTCF missense variant in a zinc finger...
10.
Vo K, Dubois S, Neuhaus J, Braunstein S, Weil B, Naranjo A, et al.
Pediatr Blood Cancer
. 2022 Feb;
69(9):e29616.
PMID: 35188340
Purpose: We sought to analyze biologic, clinical, and prognostic differences according to pattern of failure at the time of first relapse in neuroblastoma. Patients And Methods: Children <21 years diagnosed...